Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2

por Bizouarne, N, Squiban, P, Acres, B, Balloul, JM, Ohresser, MA, Figlin, R, Belldegrun, A, Herrman, R, Rochlitz, C
Publicado 2001

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

por Tartour, E, Mehtali, M, Sastre-Garau, X, Joyeux, I, Mathiot, C, Pleau, J M, Squiban, P, Rochlitz, C, Courtney, M, Jantscheff, P, Herrmann, R, Pouillart, P, Fridman, W H, Dorval, T
Publicado 2000